Skip to main content
. 2022 Jun 23;13:898493. doi: 10.3389/fimmu.2022.898493

Figure 4.

Figure 4

IGFBP7 predicts therapeutic response to immunotherapy in BLCA. (A–C) Expression levels of immune check points in the high- and low-IGFBP7 groups in the TCGA, IMvigor210, GSE32894 cohorts. (D) ICB responses in the high- and low-IGFBP7 groups using TIDE algorithm. (E–G) The enrichment scores of several immune-related signatures in the high- and low-IGFBP7 groups. (H, I) Correlation between IGFBP7 and the clinical response of cancer immunotherapy in the IMvigor210 and GSE176307 cohort. (J) Correlation between IGFBP7 and the clinical response of cancer immunotherapy in the RCC cohort and two melanoma cohorts. CR: complete response; PR, partial response; PD, progressed disease; SD, stable disease. (CR/PR means patient who are CR or PR; SD/PD means patient who are SD or PD). *p< 0.05; **p<0.01; ***p<0.001. ns, no significance; ns, p≥0.05.